VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021

July, 27 2021

BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Thursday, August 12th @ 8:30am Eastern Time Toll Free: 877-256-3294 International: 212-231-2918 Conference ID: 21995997 Webcast: http://public.viavid.com/index.php?id=145705 A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the…

Read More

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

July, 19 2021

BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the initiation of an investigator initiated trial (“IIT” or “study”) evaluating the safety and efficacy of AMZEEQ® (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne. The study is supported by VYNE and is being conducted by the Austin Institute for Clinical Research in Texas. “Isotretinoin has been widely used for the management of severe or scarring acne since its introduction as Accutane® in the 1980s. However, its teratogenic properties means that patients…

Read More